International Ophthalmology

, Volume 35, Issue 2, pp 281–285 | Cite as

Clinical outcomes of intravenous immunoglobulin therapy in refractory uveitis

  • M. Garcia-Geremias
  • E. CarreñoEmail author
  • S. J. Epps
  • R. W. J. Lee
  • A. D. Dick
Case Report


Intravenous immunoglobulin (IVIg) therapy has multiple mechanisms of immunomodulatory action. We wished therefore to assess its efficacy in a spectrum of patients with refractory uveitis. Retrospective review of clinical charts was conducted to document response to IVIg treatment in consecutive patients with treatment-refractory uveitis. Main outcome measures were control of intraocular inflammation, visual acuity, progression of the disease, and complications. Four (two male) patients, with a mean age at the beginning of the treatment of 47 years (range: 39–64), were included in the study. Indication for treatment was patients with active non-infectious uveitis refractory to steroids and immunomodulatory therapy. All patients received a course of 0.5 g/kg per day of IVIg for three consecutive days, repeating this course at a mean of 11 week (range: 2–39 weeks) intervals when indicated clinically. The median duration of the IVIg therapy was 7 months (range: 3–14 months). In three patients treatment resulted in stabilisation and prevention of progression of the disease, and additionally in two patients it facilitated a decrease in prednisolone dose. Treatment failed to induce long-term remission in one patient with recurrence of macular oedema. IVIg was well tolerated with neither immediate nor longer-term adverse events observed. In three out of four cases IVIg was an effective adjunctive therapy and well tolerated for the management of treatment-refractory uveitis.


Intravenous immunoglobulins Refractory uveitis Autoimmune retinopathy Birdshot chorioretinopathy 



This work was partly supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. All the patients involved in this study have consented to the submission of this case series to the journal.


  1. 1.
    Salama A, Mueller-Eckhardt C, Kiefel V (1983) Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 2(8343):193–195CrossRefPubMedGoogle Scholar
  2. 2.
    Jolles S, Kaveri SV, Orange J (2009) Intravenous immunoglobulins. Current understanding and future directions. Clin Exp Immunol 158(Suppl 1):68–70. doi: 10.1111/j.1365-2249.2009.04029.x CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Lemieux R, Bazin R, Neron S (2005) Therapeutic intravenous immunoglobulins. Mol Immunol 42(7):839–848. doi: 10.1016/j.molimm.2004.07.046 CrossRefPubMedGoogle Scholar
  4. 4.
    Lin MW, Kirkpatrick PE, Riminton DS (2007) How intravenous immunoglobulin is used in clinical practice: audits of two Sydney teaching hospitals. Intern Med J 37(5):308–314. doi: 10.1111/j.1445-5994.2007.01336.x CrossRefPubMedGoogle Scholar
  5. 5.
    Svetlicky N, Blank M, Zandman-Goddard G (2012) The beneficial effects of intravenous immunoglobulin for antineutrophil cytoplasmic antibody-positive vasculitis. Isr Med Assoc J 14(9):568–569PubMedGoogle Scholar
  6. 6.
    Foster CS, Ahmed AR (1999) Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 106(11):2136–2143. doi: 10.1016/S0161-6420(99)90496-7 CrossRefPubMedGoogle Scholar
  7. 7.
    Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR (2004) Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 111(7):1380–1382. doi: 10.1016/j.ophtha.2003.11.012 CrossRefPubMedGoogle Scholar
  8. 8.
    Foster CS, Chang PY, Ahmed AR (2010) Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 117(5):861–869. doi: 10.1016/j.ophtha.2009.09.049 CrossRefPubMedGoogle Scholar
  9. 9.
    Tselis A, Perumal J, Caon C, Hreha S, Ching W, Din M, Van Stavern G, Khan O (2008) Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 15(11):1163–1167. doi: 10.1111/j.1468-1331.2008.02258.x CrossRefPubMedGoogle Scholar
  10. 10.
    Shambal S, Lindner A, Zierz S (1998) Successful treatment of orbital myositis with intravenous immunoglobulins. Muscle Nerve 21(10):1359–1360CrossRefPubMedGoogle Scholar
  11. 11.
    Kleffner I, Dorr J, Duning T, Young P, Ringelstein EB, Schilling M (2014) Susac syndrome treated with subcutaneous immunoglobulin. Eur Neurol 71(1–2):89–92. doi: 10.1159/000354181 PubMedGoogle Scholar
  12. 12.
    Fox RJ, Costello F, Judkins AR, Galetta SL, Maguire AM, Leonard B, Markowitz CE (2006) Treatment of Susac syndrome with gamma globulin and corticosteroids. J Neurol Sci 251(1–2):17–22. doi: 10.1016/j.jns.2006.08.007 CrossRefPubMedGoogle Scholar
  13. 13.
    Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13(3):176–189. doi: 10.1038/nri3401 CrossRefPubMedGoogle Scholar
  14. 14.
    Sunakawa M (1989) High-dose intravenous gammaglobulin therapy for uveitis. Metab Pediatr Syst Ophthalmol 12(4):93–95PubMedGoogle Scholar
  15. 15.
    Seider N, Beiran I, Scharf J, Miller B (2001) Intravenous immunoglobulin therapy for resistant ocular Behcet’s disease. Br J Ophthalmol 85(11):1287–1288CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    LeHoang P, Cassoux N, George F, Kullmann N, Kazatchkine MD (2000) Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocular Immunol Inflamm 8(1):49–57CrossRefGoogle Scholar
  17. 17.
    Onal S, Foster CS, Ahmed AR (2006) Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocular Immunol Inflamm 14(6):367–374. doi: 10.1080/09273940601025966 CrossRefGoogle Scholar
  18. 18.
    Rosenbaum JT, George RK, Gordon C (1999) The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol 127(5):545–549CrossRefPubMedGoogle Scholar
  19. 19.
    Guy J, Aptsiauri N (1999) Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 117(4):471–477CrossRefPubMedGoogle Scholar
  20. 20.
    Dan D, Fischer R, Adler S, Forger F, Villiger PM (2014) Cyclophosphamide: as bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases. Swiss Med Wkly 144:w14030. doi: 10.4414/smw.2014.14030 PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  • M. Garcia-Geremias
    • 1
  • E. Carreño
    • 1
    Email author
  • S. J. Epps
    • 1
    • 2
  • R. W. J. Lee
    • 1
    • 2
    • 3
  • A. D. Dick
    • 1
    • 2
    • 3
  1. 1.Medical Retina and Uveitis Department, Bristol Eye HospitalUniversity Hospitals Bristol NHS Foundation TrustBristolUK
  2. 2.Faculty of Medicine and Dentistry, School of Clinical SciencesUniversity of BristolBristolUK
  3. 3.National Institute for Health ResearchBiomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of OphthalmologyLondonUK

Personalised recommendations